Compare BRCB & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | ANTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.7M | 172.9M |
| IPO Year | 2025 | 2022 |
| Metric | BRCB | ANTX |
|---|---|---|
| Price | $7.19 | $5.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $12.33 | $9.00 |
| AVG Volume (30 Days) | ★ 301.7K | 223.7K |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $200,321,000.00 | N/A |
| Revenue This Year | $27.39 | N/A |
| Revenue Next Year | $24.41 | N/A |
| P/E Ratio | $86.50 | ★ N/A |
| Revenue Growth | ★ 24.49 | N/A |
| 52 Week Low | $6.11 | $1.00 |
| 52 Week High | $26.45 | $7.19 |
| Indicator | BRCB | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 49.36 |
| Support Level | $6.89 | $4.61 |
| Resistance Level | $8.67 | $7.05 |
| Average True Range (ATR) | 0.34 | 0.38 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 52.81 | 52.94 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.